Impact of Vaccination on the Course and Outcome of COVID-19 in Patients with Multimorbidity

Author:

Lomonosov Kirill1,Lomonosova Alyona1,Mindlina Alla1,Polibin Roman1ORCID,Antipov Maksim1ORCID,Grimm Gleb1

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia

Abstract

Vaccination is the most cost-effective method of preventing COVID-19; however, data on its effect on patients with multimorbidity is limited. The aim was to evaluate the effect of vaccination against new coronavirus infection (NCI) in patients with multimorbid pathology in hospital treatment on the outcome of COVID-19 disease. An analysis was carried out of 1832 records of patients in one of the COVID-19 hospitals in Moscow for 2020–2022. Statistical analysis was carried out using the StatTech v. 3.1.3 software, and the binary logistic regression (BLR) method was used to obtain prognostic models. The median age of patients was 69 years, and 76% of them had received two vaccine doses. To assess the outcome of the disease, two prognostic models were obtained depending on the presence of a multimorbidity in patients: cardiovascular pathology and/or atherosclerosis and/or type 2 diabetes mellitus (Model 1) or atherosclerosis and/or type 2 diabetes mellitus and/or encephalopathy (Model 2), against the background of the presence or absence of vaccination against NCI. When assessing the outcome of NCI in Model 1, the odds of death decreased by 3.228 times with two doses of Sputnik V in patients with multimorbidity. According to Model 2, for patients with multimorbidity, the chances of death decreased by 3.281 times with two doses of Sputnik V. The presence of two doses of Sputnik V increased the likelihood of recovery in patients with multimorbidity by more than three times.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference25 articles.

1. (2023, September 20). COVID-19 Situation in WHO European Region. Available online: https://who.maps.arcgis.com/apps/dashboards/a19d5d1f86ee4d99b013eed5f637232d.

2. (2023, September 20). Стопкоронавирус.рф—Official Online Resource for Informing the Public about Coronavirus (COVID-19). Available online: https://стопкоронавирус.рф/information/.

3. WHO (2023, September 20). 2019-NCov Outbreak Is an Emergency of International Concern. Available online: https://reliefweb.int/report/world/2019-ncov-outbreak-emergency-international-concern.

4. Mhereeg, M., Jones, H., Kennedy, J., Seaborne, M., Parker, M., Kennedy, N., Akbari, A., Zuccolo, L., Azcoaga-Lorenzo, A., and Davies, A. (2023). COVID-19 vaccination in pregnancy: The impact of multimorbidity and smoking status on vaccine hesitancy, a cohort study of 25,111 women in Wales, UK. BMC Infect Dis., 23.

5. (2023, November 02). Multiple Long-Term Conditions (Multimorbidity): Making Sense of the Evidence. Available online: https://evidence.nihr.ac.uk/collection/making-sense-of-the-evidence-multiple-long-term-conditions-multimorbidity/.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3